APA (7th ed.) Citation

Colombo, N., Zsiros, E., Parma, G., Rulli, E., Sebastianelli, A., Bidzinski, M., . . . Hietanen, S. (2026). Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): A multicentre, randomised, double-blind, phase 3 study. Lancet, 407(10538), 1525. https://doi.org/10.1016/S0140-6736(26)00602-1

Chicago Style (17th ed.) Citation

Colombo, Nicoletta, et al. "Pembrolizumab Plus Weekly Paclitaxel in Platinum-resistant Recurrent Ovarian Cancer (ENGOT-ov65/KEYNOTE-B96): A Multicentre, Randomised, Double-blind, Phase 3 Study." Lancet 407, no. 10538 (2026): 1525. https://doi.org/10.1016/S0140-6736(26)00602-1.

MLA (9th ed.) Citation

Colombo, Nicoletta, et al. "Pembrolizumab Plus Weekly Paclitaxel in Platinum-resistant Recurrent Ovarian Cancer (ENGOT-ov65/KEYNOTE-B96): A Multicentre, Randomised, Double-blind, Phase 3 Study." Lancet, vol. 407, no. 10538, 2026, p. 1525, https://doi.org/10.1016/S0140-6736(26)00602-1.